文献速递血栓与止血

血友病基因治疗的伦理问题:一项叙述性综述

The ethics of gene therapy for hemophilia: a narrative review.
PubMed 文献 · J Thromb Haemost · 2023-01-02

该叙述性综述分析文献后识别出血友病基因治疗的三类伦理主题:对基因治疗期望过高、心理社会影响、成本与可及性;作者认为可能需要改变将基因治疗描述为治愈的叙事,并鉴于其他治疗的可及性重新评估其可取性。

要点

  • 文献分析识别出三类伦理主题:达到期望、心理社会影响、成本与可及性。
  • 目前获批产品不太可能成为永久治愈,需改变将基因治疗描述为治愈的叙事。
  • 鉴于其他治疗的可及性,作者认为需要重新评估血友病基因治疗的可取性。

核心结论

  • 作者认为可能需要改变围绕基因治疗的叙事,从将其描述为治愈改为描述为暂时缓解症状的众多治疗之一;并鉴于其他治疗的可及性,需要重新评估血友病基因治疗的可取性。

研究设计与样本

  • 叙述性综述,基于对文献的分析;欧盟于2022年8月附条件批准首个基因治疗产品上市。

主要发现

  • 识别出3个伦理主题:达到期望、心理社会影响、成本与可及性。
  • 达到期望主题描述了对基因治疗的现有希望以及当前获批产品不太可能成为永久治愈。
  • 心理社会影响主题讨论了基因治疗将影响血友病患者身份认同的担忧及其心理社会支持需求。
  • 成本与可及性主题讨论了基因治疗的预期成本效益及其对全球可及性的影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gene therapy is expected to become a promising treatment, and potentially even a cure, for hemophilia. After several years of research, the first gene therapy product has been granted conditional market authorization by the European Union in August 2022. The recent progress in the field also has implications on the ethical aspects of hemophilia gene therapy. Reviews conducted in the 2000s mainly identified questions on the ethics of conducting early-phase clinical trials. However, since then, the knowledge on safety and efficacy has improved, and the field has moved toward clinical application, a phase that has its own ethical aspects. Therefore, we conducted a narrative review to take stock of the ethical aspects of hemophilia gene therapy. Based on our analysis of the literature, we identified 3 ethical themes. The theme Living up to expectations describes the existing hopes for gene therapy and the unlikelihood of the currently approved product becoming a permanent cure. In the theme Psychosocial impacts, we discuss the fear that gene therapy will impact the identity of people with hemophilia and their need for psychosocial support. The theme Costs and access discusses the expected cost-effectiveness of gene therapy and its implications on accessibility worldwide. We conclude that it may be necessary to change the narratives surrounding gene therapy, from describing it as a cure to describing it as one of the many treatments that temporarily relieve symptoms and that there is a need to reevaluate the desirability of gene therapy for hemophilia, given the availability of other treatments.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Baas L, van der Graaf R, van Hoorn ES, et al. The ethics of gene therapy for hemophilia: a narrative review. J Thromb Haemost. 2023. PMID: 36696181. doi:10.1016/j.jtha.2022.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。